RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using (47)Sc-conjugated cetuximab. Kim DM, Lee SY, Lim JC, Cho EH, et al. BMC Cancer 2023;23:652.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim DM, Lee SY, Lim JC, Cho EH, et al. RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using (47)Sc-conjugated cetuximab. BMC Cancer 2023;23:652.
PMID: 37438719